Physician profile
Stephanie Denmark
NPI 1184006462
$1,690.76
in general payments reported to CMS, 2019-2025
25 companies · $1,199 in 2025
The $1,199 reported for 2025 was more than what 88% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $492 · 2025: $1,199.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,691.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,690.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $258.92 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $180.04 | 2024-2025 | Airsupra, Farxiga |
| Abbvie INC. | $137.86 | 2024-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $112.03 | 2024-2025 | Xifaxan |
| Lilly USA, LLC | $109.86 | 2024-2025 | Zepbound, Mounjaro |
| Pfizer INC. | $104.71 | 2024-2025 | |
| Otsuka America Pharmaceutical, INC. | $87.53 | 2024-2025 | Rexulti |
| Dexcom, INC. | $86.71 | 2024-2025 | Dexcom G6 Transmitter |
| Abbott Laboratories | $81.64 | 2025 | Freestyle Libre 3 |
| Exact Sciences Corporation | $61.87 | 2024-2025 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $51.21 | 2024-2025 | Jardiance, Synjardy |
| Bayer Healthcare Pharmaceuticals INC. | $51.08 | 2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $47.65 | 2024-2025 | Caplyta |
| Amgen INC. | $41.48 | 2024-2025 | Otezla, Repatha, Otezla |
| Esperion Therapeutics, INC. | $38.66 | 2024-2025 | Nexletol |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $37.42 | 2024 | Spravato |
| Axsome Therapeutics, INC. | $31.73 | 2025 | Auvelity |
| Phathom Pharmaceuticals, INC. | $30.00 | 2025 | Voquezna |
| Seqirus USA INC | $25.09 | 2025 | Flucelvax, Fluad |
| Radius Health, INC. | $24.36 | 2025 | |
| Actelion Pharmaceuticals US, INC. | $23.45 | 2024 | Opsumit |
| Lundbeck LLC | $18.62 | 2024 | Rexulti |
| Inspire Medical Systems, INC. | $17.22 | 2025 | Inspire |
| Merck Sharp & Dohme LLC | $16.19 | 2024 | Gardasil 9, Gardasil, Capvaxive |
| Edwards Lifesciences Corporation | $15.43 | 2025 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephanie Denmark listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.